Sponsored By

Seagen building $400m WA manufacturing plant

Seagen will spend between $350 and $400 million to construct a greenfield biomanufatckuring site in Everett, Washington.

Dan Stanton

April 25, 2022

1 Min Read
Seagen building $400m WA manufacturing plant
The town plat filed by the Everett Land Company in 1892. Image c/o WSU Libraries Digital Collections/Wikipedia

Seagen will spend between $350 and $400 million over the next three years to construct a greenfield biomanufacturing site in Everett, Washington.

Antibody-drug conjugate (ADC) pioneer Seagen (previously Seattle Genetics) will imminently begin constructing a biologics facility in Everett, Washington, close to its existing site in Bothell.

The 270,000 square-foot plant is expected to be operational in 2024 and will employ up to 200 workers to produce clinical and commercial products.

640px-Plat_of_Everett_Snohomish_County_Washington-300x204.jpg

The town plat filed by the Everett Land Company in 1892. Image c/o WSU Libraries Digital Collections/Wikipedia

“In cancer research and development, Seagen must continue to be agile and flexible, especially in manufacturing, to advance our promising pipeline of medicines for people living with cancer and bring these medicines to patients as fast as possible,” said Seagen’s CEO Clay Siegall.

“This new biomanufacturing facility is another way we are growing and expanding operations while also positioning ourselves to attract top-flight talent to drive our business priorities.”

Seagen has sat on the Everett site for almost a year, quietly signing a 20-year lease last June for the building complex to provide future additional manufacturing, laboratory, and office space.

According to the firm’s Form 10-K for the fiscal year ended December 31, 2021, Seagen expects to spend approximately $350 million to $400 million over the next three years on the site.

Along with the Bothell plant, Everett will support Seagen’s current ADC portfolio and its pipeline of 17 biologics for solid tumors and hematologic malignancies. Seagen has four ADC’s commercially available in the US, the latest approved being Tivdak (tisotumab vedotin) for cervical cancer.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.


Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.


From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.